Primary trimethylaminuria is a metabolic disorder characterized by the excessive excretion of trimethylamine, a volatile compound with a strong odor. It is due to biallelic pathogenic variants in the FMO3 gene and follows an autosomal recessive inheritance pattern. Enzyme deficiency prevents the effective conversion of trimethylamine into an odorless metabolite, causing its accumulation in various body fluids.
Trimethylaminuria
The FMO3 gene encodes flavin-containing monooxygenase 3, a microsomal enzyme expressed mainly in the liver. It uses FAD and NADPH to oxidize nitrogenous and sulfurous compounds. Among its substrates is trimethylamine, generated by the gut microbiota from dietary precursors such as choline and trimethylamine N-oxide, which it transforms into trimethylamine N-oxide, which is non-volatile and odorless.
Pathogenic variants in FMO3 reduce or abolish this activity, causing unmetabolized trimethylamine to pass into the blood and be eliminated through urine, sweat, breath, and other secretions. The primary form is inherited in an autosomal recessive manner and requires two affected alleles. Its exact prevalence is not established, and carrier frequency varies among populations. It should be distinguished from secondary or transient forms related to precursor overload, gut microbiota, liver or kidney disease, and hormonal changes.
Symptoms
The main symptom is a characteristic body odor, similar to rotting fish, which can be present from childhood or appear episodically. It usually intensifies during puberty, exercise, stress, fever, or after certain foods. In women, it can worsen around menstruation, with oral contraceptives, or during menopause. It does not usually cause physical, neurological, or developmental alterations, but it can lead to bullying, low self-esteem, isolation, anxiety, depression, and work or relationship difficulties. The intensity varies from persistent forms to mild or transient presentations.
Disease management
Currently, there is no curative treatment. Management aims to reduce trimethylamine production and volatility through an individualized and supervised diet, limiting foods rich in precursors without causing choline or folate deficiencies. Intense choline restriction should be avoided during growth, pregnancy, and lactation. Slightly acidic pH skin products, activated charcoal, copper chlorophyllin, riboflavin, and, in selected cases, short courses of antibiotics under medical supervision may be used. Psychological support, hygiene, and reduction of factors that increase sweating are also important. There are no approved targeted therapies; strategies concerning the microbiota and intestinal capture of trimethylamine are being investigated.
Genes analyzed
Bibliography
Phillips IR, Shephard EA. Primary Trimethylaminuria. GeneReviews®. Updated November 5, 2020.
Chalmers RA, Bain MD, Michelakakis H, Zschocke J, Iles RA. Diagnosis and management of trimethylaminuria (FMO3 deficiency) in children. J Inherit Metab Dis. 2006;29:162-172.
Bouchemal N, Ouss L, Brassier A, et al. Diagnosis and phenotypic assessment of trimethylaminuria, and its treatment with riboflavin: 1H NMR spectroscopy and genetic testing. Orphanet J Rare Dis. 2019;14:222.
Sidoti A, D’Angelo R, Castagnetti A, et al. Exploring Trimethylaminuria: Genetics and Molecular Mechanisms, Epidemiology, and Emerging Therapeutic Strategies. Biology. 2024;13(12):961.
